Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.

Inclusion Criteria:

• Patients with age ≥ 18 years AND

• Patients who have signed informed consent AND

• Patients with coronary artery disease requiring percutaneous treatment with coronarystents due to de novo lesions in vessels with a diameter of reference from 2.25 mmto 4.0 mm AND

• Patients with at least 2 angiographic lesions in 2 different major coronaryarteries. Or in the main branch and in one of its subsidiaries branches , as long asthose are not "downstream" of the lesion from the main branch

Exclusion Criteria:

• Express refusal of the patient to participate in the study

• Patients with ST elevation Myocardial Infarction or Cardiogenic Shock

• Patients with high thrombotic content

• Pregnant or breastfeeding patients

• Patients with complex PCI (Percutaneous Coronary Intervention )(defined as):

• Left main PC

• Chronic total PC occlusion

• Bifurcation lesion requiring 2-stent technique .

• Severe calcified lesion (need to use prior complex techniques of calciummodification such as intravascular lithotripsy, rotational/orbital atherectomy,laser.

• Patients with malignant neoplasms or other comorbid conditions with life expectancy <12 months

• Patients with a target lesion in a bypass graft

• Lesions due to restenosis

• Patients with PCI in the target vessel in the previous 9 months

• Patients with contraindication or difficulty to evaluate in the follow-up with OCT (renal failure, excessive tortuosity or lesions aorto-ostial)